DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Cediranib
Cediranib
AZD2171 (Cediranib)
Estimating the Clinical Risk of Hypertension from VEGF Signal
Phase II Study of Cediranib in Patients with Advanced Gastrointestinal Stromal Tumors Or Soft-Tissue Sarcoma
Cutting Edge in Medical Management of Cutaneous Oncology Kim Chong, MD,* Adil Daud, MD,† Susana Ortiz-Urda, MD, Phd,* and Sarah T
Combined VEGFR and MAPK Pathway Inhibition in Angiosarcoma Michael J
Ai-24 Vegfr Inhibitors Enhance Progression Of
Astrazeneca Oncology Gaining Momentum Pascal Soriot, CEO
Treating Triple-Negative Breast Cancer: Where Are We?
Changing the Destiny of HER2 Expressing Solid Tumors
Antitumor and Antiangiogenic Activity of Cediranib in a Preclinical Model of Renal Cell Carcinoma
Effects of EGFR Expression on Anti-Tumor Efficacy of Vandetanib Or Cediranib Combined with Radiotherapy (RT) in U87 Human Glioblastoma (GBM) Xenografts
Japan $62M JP (+7%): Fasenra Growth Offset Leading Biologic 200 Transfer of Symbicort Distribution Overall in New
Journal ONKO | Druckansicht
New Strategies in Sarcoma Therapy: Linking Biology and Novel Agents
Role of Vegfs/VEGFR-1 Signaling and Its Inhibition in Modulating Tumor Invasion: Experimental Evidence in Different Metastatic Cancer Models
Profile of Selumetinib and Its Potential in the Treatment of Melanoma
Safety and Efficacy of Afatinib As Add-On to Standard
Assessing the Activity of Cediranib, a VEGFR-2/3 Tyrosine Kinase Inhibitor, Against VEGFR-1 and Members of the Structurally Related PDGFR Family
Top View
Drug Discovery Model Using Molecular Orbital Computations: Tyrosine Kinase Inhibitors Clifford Fong
1 Combined MEK and VEGFR Inhibition in Orthotopic Human Lung
Currently Recruiting Clinical Trials Reference List
Improved Tumor Oxygenation and Survival in Glioblastoma Patients Who Show Increased Blood Perfusion After Cediranib and Chemoradiation
AUGUST 2020 Bone Marrow Clinical Trials
Advanced Epithelial Ovarian Cancer: from Standard Chemotherapy to Promising Molecular Pathway Targets – Where Are We Now?
Update on Phase 3 GY004 for Cediranib and LYNPARZA® (Olaparib) in Platinum-Sensitive Relapsed Ovarian Cancer
New Frontiers in Therapy of Peripheral Nerve Sheath Tumors In
Chemotherapy for Glioblastoma: Current Treatment and Future Perspectives for Cytotoxic and Targeted Agents
Combinatorial Drug Testing in 3D Microtumors Derived from GBM
Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment
Identification of Target Genes of Cediranib in Alveolar Soft Part Sarcoma Using a Gene Microarray
Enhertu Granted Priority Review in the US for the Treatment of HER2
KPCO Investigator Trials
Recurrent Glioblastoma: from Molecular Landscape to New Treatment Perspectives
Mechanisms of Immune Evasion in Breast Cancer Joshua P
Activity and Safety of Crizotinib in Patients with Alveolar Soft Part Sarcoma with Rearrangement of TFE3
Future Perspectives in Cancer Immunotherapy
Impairing Flow-Mediated Endothelial Remodeling Reduces Extravasation
An Exploratory, Open-Label Study to Assess the Effects of AZD2171
Phase II Study of Cediranib in Patients with Advanced
Targeted Therapy for NSCLC–A Double-Edged Sword?
Efficacy, Safety, Pharmacokinetics and Biomarkers of Cediranib Monotherapy In
Repurposing Tyrosine Kinase Inhibitors to Overcome Multidrug Resistance in Cancer: a Focus on Transporters and Lysosomal Sequestration
Advantages of Tyrosine Kinase Anti-Angiogenic Cediranib Over Bevacizumab: Cell Cycle Abrogation and Synergy with Chemotherapy
Sample VP-3 S10 L001 Mem.Varscan.Snp Report
Feasibility of Ultra-High-Throughput Functional Screening of Melanoma Biopsies for Discovery of Novel Cancer Drug Combinations Adam A
Phase I Clinical Trials VOLUME 14, NO
Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer and Beyond
Sunitinib Administered Prior to Radiotherapy in Patients with Non-Resectable Glioblastoma: Results of a Phase II Study
Multi-Center Randomized Phase II Study Comparing Cediranib Plus Gefitinib with Cediranib Plus Placebo in Subjects with Recurrent/Progressive Glioblastoma
Clinical Trials Appendix Q1 2019 Results Update
A Phase II Trial of Vandetanib in Children and Adults with Succinate Dehydrogenase-- Deficient Gastrointestinal Stromal Tumor John Glod1, Fernanda I
Mechanism of Cediranib–Olaparib Combo Revealed
Clinical Trials Appendix Q3 2019 Results Update
All ETCTN Trials
Rapid Development of Hypertension and Proteinuria with Cediranib, an Oral Vascular Endothelial Growth Factor Receptor Inhibitor
Study Protocol and Statistical Analysis Plan
Efficacy, Safety, Pharmacokinetics, and Biomarkers of Cediranib Monotherapy in Advanced Hepatocellular Carcinoma: a Phase II Study
A Phase 1B Study of Selumetinib in Combination With
Tyrosine Kinase Receptors in Oncology
Horizon Scanning in Oncology